Zacks: Analysts Expect Guardant Health Inc (NASDAQ:GH) Will Announce Quarterly Sales of $63.63 Million

Wall Street brokerages predict that Guardant Health Inc (NASDAQ:GH) will post $63.63 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Guardant Health’s earnings. The lowest sales estimate is $56.30 million and the highest is $68.00 million. Guardant Health reported sales of $53.98 million during the same quarter last year, which indicates a positive year over year growth rate of 17.9%. The business is expected to issue its next quarterly earnings report on Tuesday, August 4th.

On average, analysts expect that Guardant Health will report full year sales of $283.85 million for the current year, with estimates ranging from $275.50 million to $295.12 million. For the next fiscal year, analysts forecast that the firm will post sales of $379.42 million, with estimates ranging from $351.00 million to $416.10 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Guardant Health.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.10. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $55.45 million. Guardant Health had a negative net margin of 30.27% and a negative return on equity of 9.24%. The firm’s revenue was up 83.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.30) earnings per share.

A number of equities research analysts have recently weighed in on GH shares. Guggenheim started coverage on Guardant Health in a research note on Friday, February 21st. They set a “buy” rating and a $103.00 price target on the stock. Citigroup boosted their price target on Guardant Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. ValuEngine upgraded Guardant Health from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 17th. Zacks Investment Research lowered Guardant Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, SVB Leerink restated a “buy” rating and set a $130.00 price target (up previously from $125.00) on shares of Guardant Health in a research note on Friday, May 8th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $114.29.

Shares of Guardant Health stock opened at $96.91 on Friday. The company has a market capitalization of $9.17 billion, a PE ratio of -116.76 and a beta of 0.58. The company has a 50-day simple moving average of $77.94 and a two-hundred day simple moving average of $77.28. Guardant Health has a one year low of $55.90 and a one year high of $112.21.

In other Guardant Health news, CFO Derek A. Bertocci sold 21,862 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $92.53, for a total value of $2,022,890.86. Following the completion of the transaction, the chief financial officer now directly owns 84,049 shares of the company’s stock, valued at $7,777,053.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Samir Kaul sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $82.38, for a total value of $2,059,500.00. Following the completion of the transaction, the director now directly owns 1,302 shares of the company’s stock, valued at $107,258.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 691,658 shares of company stock worth $55,477,241. 13.00% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in GH. FMR LLC lifted its holdings in Guardant Health by 28.3% in the first quarter. FMR LLC now owns 464,612 shares of the company’s stock valued at $35,636,000 after acquiring an additional 102,483 shares during the period. First Trust Advisors LP raised its stake in shares of Guardant Health by 0.4% during the 1st quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock worth $5,513,000 after buying an additional 264 shares during the period. State Street Corp raised its stake in shares of Guardant Health by 13.7% during the 3rd quarter. State Street Corp now owns 502,485 shares of the company’s stock worth $32,074,000 after buying an additional 60,666 shares during the period. IFP Advisors Inc raised its stake in shares of Guardant Health by 629.7% during the 4th quarter. IFP Advisors Inc now owns 1,350 shares of the company’s stock worth $107,000 after buying an additional 1,165 shares during the period. Finally, Janney Montgomery Scott LLC raised its stake in shares of Guardant Health by 48.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,683 shares of the company’s stock worth $757,000 after buying an additional 3,166 shares during the period. 79.68% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Featured Story: Cost of Capital Explained

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply